You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Verve Therapeutics Return vs. S&P
|5 Year Annualized
Verve Therapeutics Company Info
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, Burt A. Adelman, and Barry Ticho in 2018 and is headquartered in Boston, MA.
News & Analysis
Why Verve Therapeutics Stock Crashed as Much as 30% This Week
There was a concerning development in the company's clinical trials.
Verve Therapeutics: Why Great Results Aren't Enough
The company's twist on CRISPR appears to work as intended but that didn't stop this biotech's stock price from collapsing.
After Its Stock Crashed 42% in 1 Day, Is Verve Therapeutics a Buy?
It reported some very bad news, but the market might be overreacting.
Investing in Top CRISPR Companies
These CRISPR stocks could be big winners for patient investors.
1 Cathie Wood Stock to Buy Hand Over Fist Right Now
This next-generation gene therapy stock could be a big winner.
With 1 Roadblock Down, Is Verve Therapeutics a Buy Now?
It takes more than starting a clinical trial to make for a good investment.
1 Cathie Wood Stock That Could Go Parabolic Soon
This next-gen biotech stock is barreling toward a major catalyst.
Cathie Wood Is Buying This Biotech, but Here's Why I'm Not
The risks are too high, and it'll take a while for them to be addressed.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.